Table 2 Patient demographics and comorbidities
United Kingdom | Germany | Italy | France | Spain | Belgium | Netherlands | Austria | Total | |
|---|---|---|---|---|---|---|---|---|---|
Gender % (n) | |||||||||
Female | 70.8% (46) | 79.2% (57) | 62.3% (33) | 90.9% (30) | 63.6% (7) | 63.2% (12) | 72.7% (8) | 50.0% (2) | 72.8% (195) |
Male | 26.2% (17) | 15.3% (11) | 32.1% (17) | 9.1% (3) | 9.1% (1) | 36.8% (7) | 18.2% (2) | 50.0% (2) | 22.4% (60) |
Prefer not to answer | 3.1% (2) | 5.6% (4) | 5.7% (3) | 0.0% (0) | 27.3% (3) | 0.0% (0) | 9.1% (1) | 0.0% (0) | 4.9% (13) |
Education % (n) | |||||||||
No schooling completed | 4.6% (3) | 4.2% (3) | 0.0% (0) | 0.0% (0) | 9.1% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 2.6% (7) |
Primary education (4–11 years) | 3.1% (2) | 5.6% (4) | 0.0% (0) | 3.0% (1) | 9.1% (1) | 0.0% (0) | 9.1% (1) | 0.0% (0) | 3.4% (9) |
Secondary education (11–16/18 years) | 23.1% (15) | 38.9% (28) | 30.2% (16) | 12.1% (4) | 18.2% (2) | 31.6% (6) | 27.3% (3) | 50.0% (2) | 28.4% (76) |
Further education (vocational qualification, 16–18 years) | 29.2% (19) | 20.8% (15) | 24.5% (13) | 18.2% (6) | 36,4% (4) | 21.1% (4) | 9.1% (1) | 25.0% (1) | 23.5% (63) |
Undergraduate higher education (e.g. BA, Bsc) | 20.0% (13) | 12.5% (9) | 13.2% (7) | 36.4% (12) | 9.1% (1) | 31.6% (6) | 36.4% (4) | 0.0% (0) | 19.4% (52) |
Postgraduate higher education (e.g. Masters, PhD) | 13.8% (9) | 12.5% (9) | 30.2% (16) | 27.3% (9) | 18.2% (2) | 5.3% (1) | 9.1% (1) | 25.0% (1) | 17.9% (48) |
Prefer not to answer | 6.2% (4) | 5.6% (4) | 1.9% (1) | 3.0% (1) | 0.0% (0) | 10.5% (2) | 9.1% (1) | 0.0% (0) | 4.9% (13) |
Comorbidities | |||||||||
COPD | 31.7% (39) | 35.8% (44) | 12.2% (15) | 8.9% (11) | 3.3% (4) | 3.3% (4) | 3.3% (4) | 1.6% (2) | 27.1% (123) |
Bronchiectasis | 16.8% (19) | 15.0% (17) | 35.4% (40) | 8.8% (10) | 6.2% (7) | 10.6% (12) | 6.2% (7) | 0.9% (1) | 24.9% (113) |
Asthma | 30.8% (16) | 30.8% (16) | 11.5% (6) | 11.5% (6) | 3.8% (2) | 7.7% (4) | 3.8% (2) | 0.0% (0) | 11.5% (52) |
Impaired immune system* | 18.4% (9) | 32.7% (16) | 26.5% (13) | 6.1% (3) | 6.1% (3) | 8.2% (4) | 2.0% (1) | 0.0% (0) | 10.8% (49) |
Frequent pneumonia | 11.4% (4) | 37.1% (13) | 17.1% (6) | 8.6% (3) | 5.7% (2) | 5.7% (2) | 14.3% (5) | 0.0% (0) | 7.7% (35) |
Previous tuberculosis infection | 25.0% (4) | 18.8% (3) | 31.3% (5) | 0.0% (0) | 6.3% (1) | 18.8% (3) | 0.0% (0) | 0.0% (0) | 3.5% (16) |
Cystic Fibrosis (CF) | 33.3% (4) | 8.3% (1) | 16.7% (2) | 25.0% (3) | 8.3% (1) | 0.0% (0) | 0.0% (0) | 8.3% (1) | 2.6% (12) |
Whooping cough | 33.3% (2) | 0.0% (0) | 33.3% (2) | 33.3% (2) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 1.3% (6) |
Alpha 1 antitrypsin deficiency | 20.0% (1) | 60.0% (3) | 20.0% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 1.1% (5) |
Ciliary Dyskinesia | 50.0% (1) | 50.0% (1) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.4% (2) |
HIV-positive | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
Other** | 14.6% (6) | 26.8% (11) | 19.5% (8) | 22.0% (9) | 9.8% (4) | 7.3% (3) | 0.0% (0) | 0.0% (0) | 9.0% (41) |